MX2022006403A - Metodos de tratamiento de hipertension de la arteria pulmonar. - Google Patents

Metodos de tratamiento de hipertension de la arteria pulmonar.

Info

Publication number
MX2022006403A
MX2022006403A MX2022006403A MX2022006403A MX2022006403A MX 2022006403 A MX2022006403 A MX 2022006403A MX 2022006403 A MX2022006403 A MX 2022006403A MX 2022006403 A MX2022006403 A MX 2022006403A MX 2022006403 A MX2022006403 A MX 2022006403A
Authority
MX
Mexico
Prior art keywords
methods
arterial hypertension
pulmonary arterial
treating pulmonary
patient
Prior art date
Application number
MX2022006403A
Other languages
English (en)
Spanish (es)
Inventor
Alessandro Maresta
Loïc Perchenet
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73726769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022006403(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2022006403A publication Critical patent/MX2022006403A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022006403A 2019-11-29 2020-11-27 Metodos de tratamiento de hipertension de la arteria pulmonar. MX2022006403A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962941910P 2019-11-29 2019-11-29
US202063023452P 2020-05-12 2020-05-12
US202063076149P 2020-09-09 2020-09-09
PCT/EP2020/083593 WO2021105331A1 (en) 2019-11-29 2020-11-27 Methods of treating pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
MX2022006403A true MX2022006403A (es) 2022-08-25

Family

ID=73726769

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006403A MX2022006403A (es) 2019-11-29 2020-11-27 Metodos de tratamiento de hipertension de la arteria pulmonar.

Country Status (18)

Country Link
US (1) US12485119B2 (cg-RX-API-DMAC10.html)
EP (1) EP4065119B1 (cg-RX-API-DMAC10.html)
JP (3) JP7721520B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220106974A (cg-RX-API-DMAC10.html)
CN (1) CN114728002A (cg-RX-API-DMAC10.html)
AU (1) AU2020392424A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022010311A2 (cg-RX-API-DMAC10.html)
CA (1) CA3158292A1 (cg-RX-API-DMAC10.html)
CR (1) CR20220305A (cg-RX-API-DMAC10.html)
EC (1) ECSP22051163A (cg-RX-API-DMAC10.html)
ES (1) ES2994089T3 (cg-RX-API-DMAC10.html)
IL (1) IL293271A (cg-RX-API-DMAC10.html)
JO (1) JOP20220127A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022006403A (cg-RX-API-DMAC10.html)
PE (1) PE20221320A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022551294A1 (cg-RX-API-DMAC10.html)
TW (1) TW202133851A (cg-RX-API-DMAC10.html)
WO (1) WO2021105331A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024099953A1 (en) * 2022-11-07 2024-05-16 Actelion Pharmaceuticals Ltd Combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension
KR102663470B1 (ko) * 2023-03-16 2024-05-10 주식회사 케어사이드 폐성 고혈압에 의한 심장 질환 예방 및 심장 치료용 조성물 및 이를 포함하는 기능성 제제

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1693372A1 (en) 2000-12-18 2006-08-23 Actelion Pharmaceuticals Ltd. Novel Sulfamides and their use as endothelin receptor antagonists
TWI316055B (cg-RX-API-DMAC10.html) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
ES2393117T3 (es) 2005-09-12 2012-12-18 Actelion Pharmaceuticals Ltd. Composición farmacéutica estable que comprende una pirimidina-sulfamida
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
MX350011B (es) 2008-08-13 2017-08-22 Actelion Pharmaceuticals Ltd Composiciones terapeuticas que contienen macitentan.
SG176915A1 (en) 2009-06-26 2012-01-30 Nippon Shinyaku Co Ltd Crystals
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
EA026074B1 (ru) 2010-10-15 2017-02-28 Джилид Сайэнс, Инк. Способы, включающие применение композиции амбризентана и тадалафила для лечения легочной артериальной гипертензии
CN106461677B (zh) * 2014-04-22 2018-09-11 国立大学法人东北大学 肺高血压病的检查方法
AU2016207046B2 (en) * 2015-01-13 2021-04-01 Vivus Llc Combination therapy for pulmonary hypertension
RU2763525C2 (ru) * 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
EP3897646B1 (en) * 2018-12-21 2024-05-22 Actelion Pharmaceuticals Ltd Macitentan for the treatment of pulmonary arterial hypertension

Also Published As

Publication number Publication date
ECSP22051163A (es) 2022-07-29
JOP20220127A1 (ar) 2023-01-30
CR20220305A (es) 2022-07-28
EP4065119B1 (en) 2024-09-04
JP7721520B2 (ja) 2025-08-12
PH12022551294A1 (en) 2023-11-20
TW202133851A (zh) 2021-09-16
US12485119B2 (en) 2025-12-02
JP7620758B2 (ja) 2025-01-23
JP2024153734A (ja) 2024-10-29
CA3158292A1 (en) 2021-06-03
CN114728002A (zh) 2022-07-08
KR20220106974A (ko) 2022-08-01
IL293271A (en) 2022-07-01
EP4065119A1 (en) 2022-10-05
JP2023504115A (ja) 2023-02-01
BR112022010311A2 (pt) 2022-08-16
US20230032813A1 (en) 2023-02-02
WO2021105331A1 (en) 2021-06-03
AU2020392424A1 (en) 2022-06-02
JP2025172745A (ja) 2025-11-26
ES2994089T3 (en) 2025-01-17
PE20221320A1 (es) 2022-09-08

Similar Documents

Publication Publication Date Title
MX2007002311A (es) Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos.
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
MX2020009773A (es) Terapia de combinacion.
PH12022551294A1 (en) Methods of treating pulmonary arterial hypertension
EP4696301A3 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
PT3972603T (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
WO2005030187A3 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
PE20210096A1 (es) Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
DK1699459T3 (da) Fremgangsmåde til behandling af multipel sclerose
ZA201907101B (en) Methods of preventing or treating ophthalmic diseases
MX390722B (es) Tratamiento de resistencia a diureticos.
SI3972604T1 (sl) Brutonov zaviralec tirozin kinaze za zdravljenje kronične spontane urtikarije
PH12021551180A1 (en) Methods of treating myeloproliferative disorders
NO20054371L (no) Somatostatin-dopamin kimaere analoger
WO2021023069A8 (zh) Tpk作为靶点在阿尔茨海默病的应用
EP3968985A4 (en) Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
ZA202101055B (en) Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors
UY28017A1 (es) Tratamiento terapéutico
CR20210143A (es) Utilización de un inhibidor de catepsina s contra la formación de anticuerpos anti-fármaco
CR20240023A (es) Compuestos de sulfonimidamida y usos de los mismos
MX2023009272A (es) Métodos para tratar los glioblastomas con sepiapterina.
MX2022010513A (es) Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.
TW200621261A (en) Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones
TW200633692A (en) Use of alpha-adrenergic blockers for the treatment of dysmenorrhea